[177Lu-DOTA0-Tyr3]-Octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: The value of measuring absorbed dose to the kidney

World Journal of Surgery

Volumn 34, Issue 6, 2010, Pages 1368-1372

  Swärd, Christina ^a   Bernhardt, Peter ^a   Ahlman, Håkan ^a   Wängberg, Bo ^a   Forssell Aronsson, Eva ^a   Larsson, Maria ^a   Svensson, Johanna ^a   Rossi Norrlund, Rauni ^a   Kölby, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

(177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ARTICLE; ARTIFICIAL EMBOLISM; CATHETER ABLATION; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; LIVER TRANSPLANTATION; MALE; MULTIMODALITY CANCER THERAPY; NEUROENDOCRINE TUMOR; NONPARAMETRIC TEST; PANCREAS TUMOR; TREATMENT OUTCOME;

CATHETER ABLATION; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER TRANSPLANTATION; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77955559889     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-009-0387-6     Document Type: Article

References (28)

1. Wängberg B, Westberg G, Tylén U et al (1996) Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 20:892-899, discussion 899
2. Swärd C, Johanson V, Nieveen van Dijkum E et al (2009) Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 96:517-521
3. Öberg K (2000) Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62(Suppl 1):92-97
4. Kölby L, Persson G, Franzén S et al (2003) Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687-693
5. Öberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3:863-877
6. Öberg K (1993) The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 22:941-952 (Pubitemid 24017279)
7. Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62(Suppl 1):73-78
8. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754-2762
9. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
10. Hsiao RJ, Neumann HP, Parmer RJ et al (1990) Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating twocompartment distribution. Am J Med 88:607-613
11. Kölby L, Bernhardt P, Swärd C et al (2004) Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 120:269-273
12. Stridsberg M, Öberg K, Li Q et al (1995) Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144:49-59
13. Bernhardt P, Benjegard SA, Kölby L et al (2001) Dosimetric comparison of radionuclides for therapy of somatostatin receptorexpressing tumors. Int J Radiat Oncol Biol Phys 51:514-524
14. de Jong M, Breeman WA, Valkema R et al (2005) Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46(Suppl 1):13S-17S
15. Andersson P, Forssell-Aronsson E, Johanson V et al (1996) Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med 37:2002-2006
16. Krenning EP, de Jong M, Kooij PP et al (1999) Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10(Suppl 2):S23-S29
17. van Essen M, Krenning EP, Bakker WH et al (2007) Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 34:1219-1227
18. Paganelli G, Zoboli S, Cremonesi M et al (2001) Receptormediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 28:426-434
19. Waldherr C, Pless M, Maecke HR et al (2001) The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12:941-945
20. Valkema R, De Jong M, Bakker WH et al (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32:110-122
21. Hsiao RJ, Mezger MS, O'Connor DT (1990) Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 37:955-964
22. Forssell-Aronsson E, Bernhardt P, Nilsson O et al (2004) Biodistribution data from 100 patients i.v. injected with 111In- DTPA-D-Phe1-octreotide. Acta Oncol 43:436-442
23. Forssell-Aronsson E, Fjälling M, Nilsson O et al (1995) Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med 36:7-12
24. Kölby L, Wängberg B, Ahlman H et al (1998) Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 22:679-683
25. Kubota A, Yamada Y, Kagimoto S et al (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321-1325
26. de Visser M, Verwijnen SM, de Jong M (2008) Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm 23:137-157
27. Kölby L, Bernhardt P, Ahlman H et al (2001) A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 158:745-755
28. Kölby L, Bernhardt P, Johanson V et al (2005) Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer 93:1144-1151